BioCentury | May 18, 2015
Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc .'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal...
Items per page:
1 - 1 of 1